T-cell TGF-β signaling abrogation restricts medulloblastoma progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 33, 2014, Pages

  Gate, David ^a,b   Danielpour, Moise ^b   Rodriguez Jr , Javier ^a   Kim, Gi Bum ^b   Levy, Rachelle ^b   Bannykh, Serguei ^b,c   Breunig, Joshua J ^b   Kaech, Susan M ^d,e   Flavell, Richard A ^d,e   Town, Terrence ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Cancer immunology; Neuro oncology; Neuroimmunology

Indexed keywords

CD8 ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR G1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; MALE; MEDULLOBLASTOMA; MOUSE; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

CANCER IMMUNOLOGY; NEURO-ONCOLOGY; NEUROIMMUNOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906302984     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412489111     Document Type: Article

References (64)

1. Mueller S, Chang S (2009) Pediatric brain tumors: Current treatment strategies and future therapeutic approaches. Neurotherapeutics 6(3):570-586.
2. Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ (2004) Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 22(4):706-713. (Pubitemid 41095075)
3. Northcott PA, et al. (2012) Medulloblastomics: The end of the beginning. Nat Rev Cancer 12(12):818-834.
4. Thompson MC, et al. (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924-1931. (Pubitemid 46638992)
5. Gibson P, et al. (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468(7327):1095-1099.
6. Robinson G, et al. (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409):43-48.
7. Pomeroy SL, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436-442. (Pubitemid 34100955)
8. Yoon JW, Gilbertson R, Iannaccone S, Iannaccone P, Walterhouse D (2009) Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer 124(1):109-119.
9. Gate D, Danielpour M, Levy R, Breunig JJ, Town T (2012) Basic biology and mechanisms of neural ciliogenesis and the B9 family. Mol Neurobiol 45(3):564-570.
10. Hatton BA, et al. (2008) The Smo/Smo model: Hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 68(6):1768-1776. (Pubitemid 351416562)
11. McCormick MB, et al. (1996) NeuroD2 and neuroD3: Distinct expression patterns and transcriptional activation potentials within the neuroD gene family. Mol Cell Biol 16(10):5792-5800. (Pubitemid 26315100)
12. Lin CH, et al. (2004) Regulation of neuroD2 expression in mouse brain. Dev Biol 265(1):234-245. (Pubitemid 38018834)
13. Parney IF, Hao C, Petruk KC (2000) Glioma immunology and immunotherapy. Neurosurgery 46(4):778-791.
14. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100(1-2):216-232. (Pubitemid 30038255)
15. Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136(6):1631-1647.
16. Zuber P, Kuppner MC, De Tribolet N (1988) Transforming growth factor-beta 2 downregulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18(10):1623-1626. (Pubitemid 18269349)
17. Rich JN (2003) The role of transforming growth factor-beta in primary brain tumors. Front Biosci 8:e245-260.
18. Tomita T, Ammirati M (1984) Reduction of absolute lymphocyte count in children with recurrent medulloblastoma. Am J Dis Child 138(4):392-394. (Pubitemid 14160569)
19. Kjellman C, et al. (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89(3):251-258. (Pubitemid 30430741)
20. Kehrl JH, Taylor A, Kim SJ, Fauci AS (1991) Transforming growth factor-beta is a potent negative regulator of human lymphocytes. Ann N Y Acad Sci 628:345-353.
21. Bouchard C, Fridman WH, Sautès C (1994) Mechanism of inhibition of lipopolysaccharide-stimulated mouse B-cell responses by transforming growth factor-beta 1. Immunol Lett 40(2):105-110. (Pubitemid 24175036)
22. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA (2005) Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 6(6):600-607. (Pubitemid 41710731)
23. Gorelik L, Flavell RA (2000) Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12(2):171-181. (Pubitemid 30398631)
24. Gorelik L, Fields PE, Flavell RA (2000) Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165(9):4773-4777.
25. Swain SL, Huston G, Tonkonogy S, Weinberg A (1991) Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 147(9):2991-3000.
26. Tone Y, et al. (2008) Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9(2):194-202.
27. Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005) TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201(7):1061-1067. (Pubitemid 40524674)
28. Fehérvari Z, Sakaguchi S (2004) CD4+ Tregs and immune control. J Clin Invest 114(9):1209-1217.
29. Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21(6):903-914.
30. Droege W (1971) Amplifying and suppressive effect of thymus cells. Nature 234(5331):549-551.
31. Fecci PE, et al. (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66(6):3294-3302.
32. Heimberger AB, et al. (2008) Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14(16):5166-5172.
33. Sugihara AQ, Rolle CE, Lesniak MS (2009) Regulatory T cells actively infiltrate metastatic brain tumors. Int J Oncol 34(6):1533-1540.
34. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061. (Pubitemid 36222930)
35. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330-336. (Pubitemid 36432314)
36. Fontenot JD, et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22(3):329-341. (Pubitemid 40387475)
37. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4(4):337-342. (Pubitemid 36432315)
38. Maruyama T, et al. (2011) Control of the differentiation of regulatory T cells and T(H) 17 cells by the DNA-binding inhibitor Id3. Nat Immunol 12(1):86-95.
39. Wohlfert EA, et al. (2011) GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice. J Clin Invest 121(11):4503-4515.
40. Miyazaki M, et al. (2011) The opposing roles of the transcription factor E2A and its antagonist Id3 that orchestrate and enforce the naive fate of T cells. Nat Immunol 12(10):992-1001.
41. Chang X, et al. (2011) The kinases MEKK2 and MEKK3 regulate transforming growth factor-β-mediated helper T cell differentiation. Immunity 34(2):201-212.
42. Curiel TJ (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20(2):241-246.
43. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6(4):295-307.
44. Sawada S, Scarborough JD, Killeen N, Littman DR (1994) A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell 77(6):917-929. (Pubitemid 24187689)
45. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R (1995) Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270(18):10618-10624.
46. Yokota N, et al. (1996) Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 56(2):377-383. (Pubitemid 26026368)
47. Yang ZJ, et al. (2008) Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14(2):135-145.
48. Martí E, Bumcrot DA, Takada R, McMahon AP (1995) Requirement of 19K form of Sonic hedgehog for induction of distinct ventral cell types in CNS explants. Nature 375(6529):322-325.
49. Taipale J, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406(6799):1005-1009.
50. Yauch RL, et al. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326(5952):572-574.
51. Rohatgi R, Milenkovic L, Corcoran RB, Scott MP (2009) Hedgehog signal transduction by Smoothened: Pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci USA 106(9):3196-3201.
52. Ihrie RA, et al. (2011) Persistent sonic hedgehog signaling in adult brain determines neural stem cell positional identity. Neuron 71(2):250-262.
53. Haribhai D, et al. (2007) Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 178(5):2961-2972. (Pubitemid 46333175)
54. Lin W, et al. (2007) Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 8(4):359-368. (Pubitemid 46745411)
55. Liu L, et al. (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8(2):185-189. (Pubitemid 34155131)
56. Mehal WZ, Sheikh SZ, Gorelik L, Flavell RA (2005) TGF-beta signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions. Int Immunol 17(5):531-538. (Pubitemid 41417850)
57. Sanjabi S, Mosaheb MM, Flavell RA (2009) Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 31(1):131-144.
58. Yadav M, et al. (2012) Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209(10):1713-1722.
59. Beal AM, Ramos-Hernández N, Riling CR, Nowelsky EA, Oliver PM (2012) TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentiation. Nat Immunol 13(1):77-85.
60. Venuprasad K, et al. (2008) The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 9(3):245-253. (Pubitemid 351267322)
61. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73(1):45-48. (Pubitemid 27166123)
62. Gomez CM, et al. (1997) Slow-channel transgenic mice: A model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 17(11):4170-4179. (Pubitemid 27220608)
63. Metten P, et al. (2004) Observer-rated ataxia: Rating scales for assessment of genetic differences in ethanol-induced intoxication in mice. J Appl Physiol (1985) 97(1):360-368.
64. Huang X, Ketova T, Litingtung Y, Chiang C (2010) Isolation, enrichment, and maintenance of medulloblastoma stem cells. J Vis Exp Sep 1(43).